The Simultaneous Inhibition of Solute Carrier Family 6 Member 19 and Breast Cancer Resistance Protein Transporters Leads to an Increase of Indoxyl Sulfate (a Uremic Toxin) in Plasma and Kidney
Drug Metabolism and Disposition · 2024
DOI: 10.1124/dmd.124.001813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2024. Verfasst von Qingping Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-…. Hauptthemen laut MEDLINE: Amino Acid Transport Systems, Neutral, Breast Neoplasms, Indican, Kidney. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Solute carrier family 6 member 19 (SLC6A19) inhibitors are being studied as therapeutic agents for phenylketonuria. In this work, a potent SLC6A19 inhibitor (RA836) elevated rat kidney uremic toxin indoxyl sulfate (IDS) levels by intensity (arbitrary unit) of 13.7 ± 7.7 compared with vehicle 0.3 ± 0.1 (P = 0.01) as determined by tissue mass spectrometry imaging analysis. We hypothesized that increased plasma and kidney levels of IDS could be caused by the simultaneous inhibition of both Slc6a19 and a kidney IDS transporter responsible for excretion of IDS into urine. To test this, we first confirmed the formation of IDS through tryptophan metabolism by feeding rats a Trp-free diet. Inhibiting Slc6a19 with RA836 led to increased IDS in these rats. Next, RA836 and its key metabolites were evaluated in vitro for inhibiting kidney transporters such as organic anion transporter (OAT)1, OAT3, and breast cancer resistance protein (BCRP). RA836 inhibits BCRP with an IC50 of 0.045 μM but shows no significant inhibition of OAT1 or OAT3. Finally, RA836 analogs with either potent or no inhibition of SLC6A19 and/or BCRP were synthesized and administered to rats fed a normal diet. Plasma and kidney samples were collected to quantify IDS using liquid chromatography-mass spectrometry. Neither a SLC6A19 inactive but potent BCRP inhibitor nor a SLC6A19 active but weak BCRP inhibitor raised IDS levels, whereas compounds inhibiting both transporters caused IDS accumulation in rat plasma and kidney, supporting the hypothesis that rat Bcrp contributes to the excretion of IDS. In summary, we identified that inhibiting Slc6a19 increases IDS formation, while simultaneously inhibiting Bcrp results in IDS accumulation in the kidney and plasma. SIGNIFICANCE STATEMENT: This is the first publication to decipher the mechanism for accumulation of indoxyl sulfate (IDS) (a uremic toxin) in rats via inhibition of both Slc6a19 and Bcrp. Specifically, inhibition of Slc6a19 in the gastrointestinal track increases IDS formation, and inhibition of Bcrp in the kidney blocks IDS excretion. Therefore, we should avoid inhibiting both solute carrier family 6 member 19 and breast cancer resistance protein simultaneously in humans to prevent accumulation of IDS, a known risk factor for cardiovascular disease, psychic anxiety, and mortality in chronic kidney disease patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Dru…
ORCID-Profile: Qingping Wang
Zitieren
APA
Wang, Q., Munteanu, B., Marker, A., Luo, Y., Holz, C., Kane, J. L., Kuntzweiler, T., Poulton, E. J., Sedic, M., Jayyosi, Z., Riedel, J., & Fretland, J. (2024). The Simultaneous Inhibition of Solute Carrier Family 6 Member 19 and Breast Cancer Resistance Protein Transporters Leads to an Increase of Indoxyl Sulfate (a Uremic Toxin) in Plasma and Kidney. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.124.001813
Vancouver
Wang Q, Munteanu B, Marker A, Luo Y, Holz C, Kane JL, et al. The Simultaneous Inhibition of Solute Carrier Family 6 Member 19 and Breast Cancer Resistance Protein Transporters Leads to an Increase of Indoxyl Sulfate (a Uremic Toxin) in Plasma and Kidney. Drug Metabolism and Disposition. 2024. doi:10.1124/dmd.124.001813
BibTeX
@article{Wang2024,
author = {Wang, Qingping and Munteanu, Bogdan and Marker, Alexander and Luo, Yongyi and Holz, Constanze and Kane, John L and Kuntzweiler, Theresa and Poulton, Emma-Jane and Sedic, Maja and Jayyosi, Zaid and Riedel, Jens and Fretland, Jennifer},
title = {The Simultaneous Inhibition of Solute Carrier Family 6 Member 19 and Breast Cancer Resistance Protein Transporters Leads to an Increase of Indoxyl Sulfate (a Uremic Toxin) in Plasma and Kidney},
journal = {Drug Metabolism and Disposition},
year = {2024},
doi = {10.1124/dmd.124.001813}
}
EUVIMED